Amneal Will Go After 505(b)(2) Opportunity Under Patels’ Leadership
Capitalizing on opportunities in the US hybrid 505(b)(2) market will be central to Amneal’s strategy to revive its fortunes now its founders, brothers Chirag and Chintu Patel, have again taken the helm.
You may also be interested in...
Endo’s Par has partnered with Allergan to launch an authorized generic of Carafate sucralfate oral suspension in the US, competing directly with the first generic version recently launched by Amneal.
After receiving FDA approval for its generic aminocaproic acid with 180 days of exclusivity under the agency’s Competitive Generic Therapy pathway, Amneal has launched the rival to Amicar. At the same time, it has also begun selling a generic version of Revatio and has also claimed the first generic rival to Carafate.
Allergan has tried to go after alopecia in the past; Exicure brings a new spherical nucleic acid (SNA) technology. In other recent deals, AstraZeneca sells Seroquel, Losec rights to Germany’s Cheplapharm.